
γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.
Legislation expands reimbursement, but concerns about liability, eligibility and privacy might constrain its broad range expansion





